Signals
Every pharma-relevant, de-duplicated event surfaced so far, primary source first. Client-scoped signals are never shown here.
ASTRAZENECA PLC · ENHERTU APPROVED IN TWO HER2+ EARLY BC SETTINGS
ASTRAZENECA PLC · BAXFENDY APPROVED IN THE US FOR HYPERTENSION
ASTRAZENECA PLC · CAMIZESTRANT RECOMMENDED FOR BREAST CANCER IN EU
ASTRAZENECA PLC · ENHERTU RECOMMENDED IN EU FOR HER2+ SOLID TUMOURS
ASTRAZENECA PLC · DATROWAY APPROVED IN US FOR 1L TRIPLE-NEGATIVE BC
ASTRAZENECA PLC · US FDA DECISION DATE ON CAMIZESTRANT EXTENDED
ASTRAZENECA PLC · IMFINZI APPROVED IN US FOR EARLY BLADDER CANCER
ASTRAZENECA PLC · TRUQAP APPROVED IN US FOR PROSTATE CANCER
ASTRAZENECA PLC · DATROWAY RECOMMENDED FOR APPROVAL IN EU FOR TNBC
ASTRAZENECA PLC · ENHERTU APPROVED IN EU FOR HER2+ SOLID TUMOURS
ELI LILLY & Co · 8-K: Results of Operations and Financial Condition; Financial Statements and Exhibits
CompaniesEli Lilly & Co
ELI LILLY & Co · 8-K: Results of Operations and Financial Condition; Financial Statements and Exhibits
CompaniesEli Lilly & CoAssetsMounjaroZepboundEbglyssJaypircaKisunlaOmvohInluriyoFoundayoRetatrutideRetevmoVERVE-102Diseasesatopic dermatitischronic lymphocytic leukemiaobesitytype 2 diabetespancreatic cancerulcerative colitissleep-wake disorders